Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment
- PMID: 11261421
- DOI: 10.1212/wnl.56.4.431
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment
Abstract
Hereditary amyloidoses form a clinically and genetically heterogeneous group of autosomal dominantly inherited diseases characterized by the deposit of insoluble protein fibrils in the extracellular matrix. They typically present with polyneuropathy, carpal tunnel syndrome, autonomic insufficiency, and cardiomyopathy and gastrointestinal features, occasionally accompanied by vitreous opacities and renal insufficiency. Other phenotypes are characterized by nephropathy, gastric ulcers, cranial nerve dysfunction, and corneal lattice dystrophy. Rarely, involvement of the leptomeningeal or cerebral structures dominates the clinical picture. The age at onset is as early as 17 and as late as 78 years. The basic constituents of amyloid fibers are physiologic proteins that have become amyloidogenic through genetically determined conformation changes. Mutated transthyretin (TTR), formerly termed prealbumin, is the most frequent offender in hereditary amyloidosis. Orthotopic liver transplantation (OLT) stops the progression of the disease, which is otherwise invariably fatal, by removing the main production site of amyloidogenic protein. The indications for OLT and its success depend on the grade of cardiovascular and autonomic dysfunction at the time of surgery, age, comorbidity, and type of mutation. Alternative treatment modalities with drugs stabilizing the native tetrameric conformation of TTR and inhibiting fibril formation are currently being studied.
Similar articles
-
[Hereditary amyloidoses associated with transthyretin mutations].Nervenarzt. 2002 Oct;73(10):930-6. doi: 10.1007/s00115-002-1345-9. Nervenarzt. 2002. PMID: 12376880 Review. German.
-
Liver transplantation for hereditary transthyretin amyloidosis.Liver Transpl. 2000 May;6(3):263-76. doi: 10.1053/lv.2000.6145. Liver Transpl. 2000. PMID: 10827225 Review.
-
Transthyretin Ile73Val is associated with familial amyloidotic polyneuropathy in a Bangladeshi family. Mutations in brief no. 158. Online.Hum Mutat. 1998;12(2):135. doi: 10.1002/(SICI)1098-1004(1998)12:2<135::AID-HUMU10>3.0.CO;2-6. Hum Mutat. 1998. PMID: 10694917
-
Hereditary transthyretin-related amyloidosis.Acta Neurol Scand. 2019 Feb;139(2):92-105. doi: 10.1111/ane.13035. Epub 2018 Oct 23. Acta Neurol Scand. 2019. PMID: 30295933
-
Potential treatment of transthyretin-type amyloidoses by sulfite.Neurogenetics. 1999 Sep;2(3):183-8. doi: 10.1007/s100480050081. Neurogenetics. 1999. PMID: 10541593 Clinical Trial.
Cited by
-
Hereditary Transthyretin-Related Amyloidosis Ongoing Observational Study: A Baseline Report of the First 3167 Participants.J Clin Med. 2024 Oct 17;13(20):6197. doi: 10.3390/jcm13206197. J Clin Med. 2024. PMID: 39458146 Free PMC article.
-
Tyr78Phe Transthyretin Mutation with Predominant Motor Neuropathy as the Initial Presentation.Case Rep Neurol. 2011 Feb 23;3(1):62-8. doi: 10.1159/000324925. Case Rep Neurol. 2011. PMID: 21490715 Free PMC article.
-
Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches.Neurol Ther. 2018 Jun;7(1):141-154. doi: 10.1007/s40120-018-0096-x. Epub 2018 Apr 2. Neurol Ther. 2018. PMID: 29611130 Free PMC article.
-
Gastrointestinal Amyloidosis: Approach to Treatment.Curr Treat Options Gastroenterol. 2003 Feb;6(1):17-25. doi: 10.1007/s11938-003-0029-2. Curr Treat Options Gastroenterol. 2003. PMID: 12521568
-
Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases.Int J Mol Sci. 2019 Jun 18;20(12):2982. doi: 10.3390/ijms20122982. Int J Mol Sci. 2019. PMID: 31216785 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous